Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Effects of valsartan on left ventricular internal diastolic diameter/body surface area (LVIDd/BSA) and ejection fraction (EF) compared to placebo by co-treatment group: change from baseline to end point. The histobars represent mean changes (adjusted for effects for treatment group, pooled center, baseline value, baseline use of angiotensin-converting enzyme inhibitor [ACEI] and/or beta-blocker [BB], and treatment-by-baseline value interaction by analysis of covariance) between baseline values and those at end point (last observation available carried forward) for co-treatment subgroups randomized to valsartan (black bars) and placebo (white bars) groups. Baseline values at each observation period are adjusted for the number of patients with available end point data. Change is expressed in absolute units for EF (%) and LVIDd/BSA (cm/m2). The p values for the valsartan versus placebo comparison are determined from least-squares mean change. Subgroups are designated by (+) = co-treatment and (–) = not a co-treatment with ACEI and BB.
|
